

## DECREASED BREADTH OF THE ANTIBODY RESPONSE TO THE SPIKE PROTEIN OF SARS-CoV-2 AFTER REPEATED VACCINATION

Lydia Horndler<sup>1</sup>, Pilar Delgado<sup>1</sup>, Salvador Romero-Pinedo<sup>2</sup>, Marina Quesada<sup>2</sup>, Ivaylo Balabanov<sup>1</sup>,  
Rocío Laguna-Goya<sup>3</sup>, Patricia Almendro-Vázquez<sup>3</sup>, Miguel A. Llamas<sup>4</sup>, Manuel Fresno<sup>1</sup>, Estela  
Paz-Artal<sup>3,5</sup>, Hisse M. van Santen<sup>1</sup>, Stela Álvarez<sup>2</sup>, Asunción Olmo<sup>2</sup> and Balbino Alarcón<sup>1</sup>

<sup>1</sup>Centro de Biología Molecular Severo Ochoa, Consejo Superior de Investigaciones Científicas (CSIC), Universidad Autónoma de Madrid, 1 Nicolás Cabrera, 28049 Madrid, Spain

<sup>2</sup>VITRO SA, Avenida del Conocimiento 100, PT de la Salud, 18016 Granada, Spain

<sup>3</sup>Instituto de Investigación Sanitaria Hospital 12 de Octubre (imas12), 28041 Madrid, Spain

<sup>4</sup>EMPIREO Diagnóstico Molecular SL, 127 Fuencarral Street, 28004 Madrid, Spain

<sup>5</sup>Department of Immunology, Ophthalmology and ENT, Universidad Complutense de Madrid, Madrid, Spain

Correspondence should be addressed to B.A. ([balarcon@cbm.csic.es](mailto:balarcon@cbm.csic.es))

Centro de Biología Molecular, Nicolás Cabrera 1, Universidad Autónoma de Madrid, Cantoblanco, Madrid 28049, Spain. Phone: 34-911964555; FAX: 34-911964420

**Running Title:** Decreased breadth after boost

## **ABSTRACT**

The rapid development of vaccines to prevent infection by SARS-CoV-2 virus causing COVID-19 makes necessary to compare the capacity of the different vaccines in terms of development of a protective humoral response. Here, we have used a highly sensitive and reliable flow cytometry method to measure the titers of antibodies of the IgG1 isotype in blood of healthy volunteers after receiving one or two doses of the vaccines being administered in Spain. We took advantage of the multiplexed capacity of the method to measure simultaneously the reactivity of antibodies with the S protein of the original strain Wuhan and the variants B.1.1.7 (Alpha), B.1.617.2 (Delta) and B.1.617.1 (Kappa). We found significant differences in the titer of anti-S antibodies produced after a first dose of the vaccines ChAdOx1 nCov-19/AstraZeneca, mRNA-1273/Moderna, BNT162b2/Pfizer-BioNTech and Ad26.COV.S/Janssen. Most important, we found a relative reduction in the reactivity of the sera with the Alpha, Delta and Kappa variants, versus the Wuhan one, after the second boosting immunization. These data allow to make a comparison of different vaccines in terms of anti-S antibody generation and cast doubts about the convenience of repeatedly immunizing with the same S protein sequence.

**Keywords:** SARS-CoV-2 / S protein / flow cytometry method / vaccines / antibody breadth

## INTRODUCTION

Vaccines to prevent the worst effects of infections by SARS-CoV-2 virus causing COVID-19 have been rapidly developed. This unprecedented fast development of vaccines has allowed a significant reduction in the number of deaths caused by COVID-19 as well as in the number of patients admitted to the intensive care units of hospitals. In Spain, the immunity reached by the widespread vaccination, and immunity due to previous infections, is likely responsible for the low number of deaths caused by the so-called the fifth-wave by the end of July 2021, in spite reaching a number of reported infections similar to that of previous waves in the fall of 2020 and beginning of year 2021 that caused a much higher number of deaths (<https://covid19.who.int/region/euro/country/es>). The vaccines that have been more commonly administered in Spain are the mRNA vaccines BNT162b2 (BNT) generated by BioNTech/Pfizer, mRNA-1273 by Moderna, and the adenovirus-based vaccines ChaAdOx1 nCoV-19 (ChAd) and Ad26.COV2.S (Ad26) by Oxford University/AstraZeneca and Janssen/Johnson&Johnson, respectively. All vaccines were demonstrated to be safe and protective in clinical trials<sup>1-4</sup>, although reports of rare cases of thrombotic thrombocytopenia associated to both the ChAd and Ad26 vaccines have been published<sup>5,6</sup>. However, the emergence of variants of concern (VOC) of SARS-CoV-2, specifically the Delta variant (B.1.617.2) with a very high transmission capacity<sup>7</sup> is threatening the vaccination strategies in Europe and the USA, given the fact that the efficacy of vaccines against the Delta variant is reduced<sup>8</sup>, and fully vaccinated people can become infected and spread the virus efficiently to others<sup>9</sup>. The possibility of giving a third boosting vaccination to immunosuppressed patients to increase the titers of antibodies to the spike (S) protein is being considered<sup>10</sup>. Moreover, the spread of the Delta variant even in fully vaccinated people is making authorities of different countries consider the possibility of administering a third dose to the general population (<https://english.elpais.com/society/2021-07-23/everything-pointing-to-need-for-a-third-covid-19-vaccine-dose-says-spanish-health-minister.html>). The capacity of the Delta variant to infect

vaccinated individuals seems to correlate with its ability to escape neutralization by antibodies produced in response to vaccines<sup>7</sup>.

Serological tests are usually established by detecting the presence of viral antigen-specific IgG or IgM in the serum of individuals using recombinant fragments of the S or N proteins and tests based on ELISA or lateral flow assay<sup>11,12</sup>. A disadvantage of those tests is that neutralizing antibodies are not directed against the N protein and that recombinant fragments of the S protein miss the quaternary structure of the protein trimer, which is the native form of the spike protein in the viral envelope. Therefore, part of the neutralizing antibodies directed against the native S trimer could be missed in serological tests based on the expression of recombinant proteins. Recently, we have described a flow cytometry (FC) test that makes use of the cell line of hematopoietic origin Jurkat to express the native S protein of SARS-CoV-2 together with a truncated form of the human EGF receptor (huEGFRt) as a normalizing tool<sup>13</sup>. The method allows the accurate determination of seropositivity and the measurement of antibody titers in sera from post-convalescent patients<sup>13</sup>. Here, we have used this FC method to compare the production of antibodies against the S protein in response to the prime immunization and the booster immunization of the four most common vaccines being used in Spain. In addition, we have used the multiplexed capacity of the method to simultaneously measure the reactivity of sera from vaccinated individuals with the S protein of the original Wuhan isolate versus the Alpha, Delta and Kappa isolates as example of VOC. Our results help to stir the debate about the convenience of a third dose of the same vaccines.

## RESULTS

### Comparison of IgG1 anti-S titers in response to the four (ChaAd, Moderna, BNT and Ad26) vaccines

We previously used a lentiviral vector to express the full spike “S” protein of SARS-CoV2 with the original Wuhan-1 sequence, followed by a truncated human EGFR protein (huEGFRt) linked by a T2A self-cleaving sequence in transduced cells<sup>13</sup>. This system allows expression of the two proteins from a monocistronic mRNA. We produced transducing supernatants to express the construct in the human leukemic cell line Jurkat. Taking advantage of the fact that the expression of S protein is coupled to that of huEGFRt, we calculated a ratio of mean fluorescence intensities of antibodies against S versus an antibody against huEGFR as direct estimation of the relative quantity of immunoglobulins against the S protein in sera or other fluids from different donors. Using this system, we interrogated what was the relative humoral response, in terms of IgG1 production, to the different vaccines used in Spain from January to August 2021. Since the Ad26.COV2.S (Ad26) vaccine was initially planned to be given in one dose and not in two, prime-boost, as the other three vaccines (BNT162b2 [BNT], mRNA-1273 [Moderna], and ChaAdOx1 nCov-19 (ChAd)), we first compared the titer of antibodies elicited in vaccinated healthy individuals 3-4 weeks after the first dose. We found that ChAd (n=37) induced lower titers of IgG1 antiS antibody than Moderna (n=54) and BNT (n=75) (Figure 1A). However, the titers elicited in response to ChAd and Ad26 (n=11) were not significantly different. Compared to the titer of antibody present in a cohort of patients recovered from SARS-CoV-2 infection between March and May 2020 (<https://covid19.who.int/region/euro/country/es>) (Patients 2020, n=58, Figure 1A), vaccination with one dose of ChAd elicited significantly lower titers ( $P<0.0001$ , One-way ANOVA test). By contrast, one dose of either BNT or Moderna induced higher titers of antibody than those present in Patients 2020. Unfortunately, the number of samples in the Ad26 group was insufficient to establish a significant comparison with the Patients 2020 cohort.

Altogether, these data suggest that the two RNA vaccines (BNT and Moderna) are more efficient than the two adenovirus-based vaccines (Ad26 and ChAd) at inducing IgG1 anti-S antibodies.

We next compared the titers of anti-S IgG1 generated in response to a priming and a booster doses of the ChAd, Moderna and BNT vaccines. The second dose of ChAd vaccine (PD2; n=39) substantially increased the titer of antibodies to a level comparable to those of Patients 2020 and to those of individuals vaccinated with two doses of Moderna (PD2; n=52; Figure 1B). Nonetheless, the antibody titers elicited by two doses of BNT (PD2, n=119) were still significantly higher than those generated in response to two doses of ChAd (Figure 1B).

Interestingly, the titers of IgG1 generated in response to two doses (PD2) of either Moderna or BNT, were not significantly higher than those generated in response to the first priming dose (PD1, Figure 1B). Those results suggest that, in terms of IgG1 anti-S titers, there is a clear benefit of administering two doses of ChAd but not of administering two doses of Moderna or BNT.

### **IgG1 titers against the S protein of the Alpha (B.1.1.7) VOC produced after priming-booster vaccination**

The flow cytometry Jurkat-S method can be easily multiplexed to measure simultaneously the generation of different antibodies to a single protein (REF) or to several proteins. We decided to use this property to measure the generation of antibodies against the S protein of the Wuhan strain in comparison with the antibodies able to bind to the S protein of the Alpha (B.1.1.7) VOC. We thought this comparison might be relevant given that the present vaccines were all generated against the Wuhan strain sequence. The S protein sequence of the Alpha VOC differs in just 7 positions from that of the Wuhan strain (Figure EV1). The Alpha VOC became dominant in Spain during the spring of 2021 (<https://theconversation.com/the-uk-variant-is-likely-deadlier-more-infectious-and-becoming-dominant-but-the-vaccines-still-work-well-against-it-156951>).and therefore, we included in this and previous experiments a cohort of sera from

patients recovered from infection by SARS-CoV-2 between March and May 2021 (Patients 2021, n=20, Figure 1 and 2).

In order to detect the presence of antibodies against the S protein of the Alpha VOC, we cloned the S sequence of the variant (Fig. EV1) into the same lentiviral vector used to generate the original Jurkat-S cells (REF) but replaced the huEGFRt reporter by EGFP, and generated Jurkat cells stably expressing the S protein of the Alpha variant and EGFP. Using this new Jurkat-S cells (from now on termed Jurkat-S[Alpha]) we could measure the titers of IgG1 antibody generated against the S protein of the Alpha VOC after prime-boost vaccination. We found similar results to those for the Wuhan strain (compare Fig. 2A with Fig. 1B), namely that the second dose of ChAd significantly increased the titer of antibodies compared to the first dose and that the second dose of Moderna and BNT did not result in a significant increase of IgG1 anti-S titers compared to the first, priming dose ( $P=0.43$  and  $P=0.92$ , respectively; One-way ANOVA test).

Taking advantage of the distinct markers used for Jurkat-S(Wuhan) and Jurkat-S(Alpha) cells (EGFR and EGFP, respectively), we could mix equal numbers of both cell lines and incubate the cell mixture with dilutions of sera of patients recovered from infection with SARS-CoV-2 or vaccinated. The analysis by flow cytometry allowed to gate on the GFP+ cells to calculate the ratio of [fluorescence anti-S/GFP fluorescence] as a measurement of the titer of antibodies of the IgG1 isotype against the S protein of the Alpha variant (Fig. 2B). Simultaneously, we could gate on the EGFR+ cells to calculate the ratio of [fluorescence anti-S/fluorescence anti-EGFR] as a measurement of the titer of antibodies of the IgG1 isotype against the S protein of the Wuhan strain. The combination of Jurkat-S(Wuhan) and Jurkat-S(Alpha) cells in the same experiment allows to calculate a ratio of ratios (S/GFP vs S/EGFR) that serves to compare sera from vaccinated volunteers in terms of their relative reactivity with the S protein of the Wuhan and Alpha VOC. Interestingly, the second dose of Moderna and the second dose of BNT caused a relative decrease in the reactivity of the antibodies with the Alpha VOC in comparison with the

Wuhan-1 isolate (Fig. 2C). The second dose of ChAd did not cause either an increase or a decrease in the relative recognition of the S protein of Alpha compared to Wuhan.

A comparison of the relative reactivity of sera from vaccines with those of people recovered from infection in 2020 and 2021, showed that antibodies produced in response to the second dose of either of the three vaccines were relatively less reactive with the Alpha strain than those produced by natural infection not only in 2021 but also in 2020 (Fig. 2C). Those results suggest that the booster immunization with the second dose of the three vaccines, based on the sequence of the Wuhan strain, might impoverish the reactivity of the antibodies with emergent VOC of SARS-CoV-2.

#### **General decrease of relative reactivity against VOCs after booster vaccination**

To determine if the detected decrease in anti-S (Alpha) relative reactivity after the second dose of vaccines was also holding true for more recent VOCs of SARS-CoV-2, we modified the Jurkat-S system to measure IgG1 binding to four variants: Wuhan, Alpha, Delta (B.1.617.2) and Kappa (B.1.617.1). In order to be able to distinguish Jurkat expressing the S protein of the Delta and Kappa variants from the Wuhan and Alpha ones, using the same lentiviral vectors with the EGFR and EGFP markers, we transduced a Jurkat CD3negative cell line generated in our lab by CRISPR/Cas9 deletion of the CD3 $\zeta$  subunit of the TCR. Those CD3- Jurkat cells were transduced with the lentiviral vectors co-expressing the S protein from Delta VOC and EGFR or co-expressing the S protein from Kappa VOC and EGFP. Using this strategy, we could mix the four Jurkat-S cell lines to incubated them simultaneously with serum samples and later to measure IgG1 binding to the 4 VOCs using CD3, EGFR and GFP markers (Figure 3). Figure 3, illustrates how the positive control serum and a negative control serum stain the four VOC. A positive serum containing IgG1 binding to any of the 4 VOCs produces a diagonal, whereas a negative serum produces a flat line (REF).

The effect of vaccination on the relative recognition of the S protein of the Alpha, Delta and Kappa VOC versus that of the Wuhan strain was followed in sera from volunteers of nursing homes who had recovered after infection in 2020 and 2021 and were later vaccinated with BNT (Table 1). Serum samples were taken just before vaccination (pre-Vacc, n=46, Figure 4), 15-21 days after the first dose (PD1, n=49) and 4 weeks after the second dose (PD2, n=70) of the BNT vaccine.

The first dose of BNT resulted in a significant increase in antibody reactivity against the Alpha and Kappa VOCs but not against the Wuhan and Delta ones (Fig. 4A). Compared to the pre-vaccination samples, the second dose of BNT (PD2) resulted in significantly increased antibody titers against the four VOCs, although the differences between antibody titers induced after PD1 and PD2 were not obvious for the Delta and Kappa ones (Figure 4A). Indeed, the relative reactivity of IgG1 antibodies with the Alpha, Delta and Kappa VOCs compared with that of the Wuhan strain, was significantly reduced after the second dose of BNT compared to the first one (PD1 vs PD2, Figure 4B). These results with samples from vaccinated donors of nursery homes support the Figure 2C data suggesting that the booster vaccination results in a relative loss of recognition of the Alpha, Delta, and Kappa VOC.

## DISCUSSION

In this study we have measured the production of antibodies of the IgG1 isotype to the spike protein of SARS-CoV-2 in response to the four different vaccines most frequently used in Spain. We have compared those data with antibodies present in sera from patients recovered from infection during the first wave of the COVID-19 pandemic in March-June 2020 and with sera from patients recovered from infection during the fourth wave between March-May 2021. Our results show that a priming first dose of the mRNA vaccines BNT/Pfizer and Moderna significantly induced a higher antibody response against the S protein of the Wuhan strain than the two adenovirus-based vaccines ChAd and Ad26, and superior to the titers found in the cohorts of 2020 and 2021 patients. The booster immunization with a second dose did not increase the average titer of antibodies except for the ChAd vaccine. The booster immunization with ChAd resulted in antibody titers that were similar to those generated in response to the booster immunization with Moderna or to the patient cohorts of 2020 and 2021, but still lower than the titers generated in response to the booster immunization with BNT. Therefore, in summary, our results indicate that two doses of the ChAd, BNT and Moderna vaccines are able to induce antibody titers against the original Wuhan strain equal or even superior to those found in post-convalescent patients. However, the message is different when we compared the relative reactivity of the antibodies against the Alpha, Delta and Kappa variants versus the Wuhan strain. Although antibodies made in response to vaccines based on the original Wuhan strain sequence do also bind the other three variants, suggesting that most epitopes are conserved between the vaccine and the variant sequences, there is a relative loss of reactivity with the three VOCs compared to the Wuhan strain occurring upon administration of the booster dose of vaccine. This is somehow expected since repeated immunization with the same antigen sequence leads to the generation of higher affinity antibodies that fit better the epitopes of the immunogen. This increase in affinity has the negative side effect of reducing the “breadth” of the antibodies, that is, their capacity to bind to epitopes that differ slightly from those of the

immunogen. Such effect of generating high-affinity antibodies that are however strain-specific has been widely documented in the search of broadly neutralizing antibodies for the human immunodeficiency virus (HIV)<sup>14</sup>. The long-term struggle, and still unsuccessful, to generate a vaccine that prevents infection by the tremendous diversity of clades and mutants of HIV, with the general conclusion that the tested vaccines are effective to prevent infection by the strain used for immunization but not by the myriad of variants found in the field<sup>15</sup>. Another example is the result of vaccination with inactivated influenza virus isolated in immunization campaigns, that result in an efficient neutralization of that particular seasonal variant of influenza but results in reduced capacity to neutralize other variants<sup>16</sup>. By contrast, antibody responses to natural infection are broad and exhibit different immunodominance patterns<sup>16</sup>. Another example of the different breadth in the antibody responses elicited by natural infection versus vaccination is In regard to COVID-19, a broad and sustained polyantigenic immunoreactivity against the S protein and other viral proteins has also been found in COVID-19 patients, in this case associated to the severity of symptoms<sup>17</sup>. Our follow-up of the cohort of residents in nursing homes that were vaccinated with two doses of BNT shows that the two doses of vaccine increased the titers of anti-S antibodies against all the four variants. However, compared with the effect of the first dose, the second dose of vaccine did not result in further increases in the antibody titer against the Delta and Kappa variants and had the negative counterpart of reducing the relative reactivity of the antibodies with all three VOCs. This is relevant since the Alpha variant first and the Delta variant later, have been the most rapidly expanding VOCs in Europe and the USA in 2021 (<https://www.cdc.gov/coronavirus/2019-ncov/science/science-briefs/fully-vaccinated-people.html>). Interestingly, a recent study using an assay similar to the Jurkat-S FC assay but based on the human B cell line Ramos, has also shown that booster vaccination with BNT increases the titer of anti-S antibodies against the Wuhan strain but not against the Alpha and Beta variants<sup>18</sup>.

Although our study is limited to measuring the presence of IgG1 against the S protein of SARS-CoV-2, we think our results are relevant to evaluate the overall humoral response, given that IgG1 is the most abundant immunoglobulin in human blood and has potent effector capacities by being able to both fix complement and bind to Fc receptors<sup>19</sup>. Our results showing a loss of relative reactivity with the current VOCs suggest that third doses of the present vaccines, based on the Wuhan sequence, to the general population might not be the best approach to increase the immunity to the emerging VOCs. In our opinion, a third dose should be limited to the population that has been demonstrated to have been poorly responsive to the first two prime and boost doses and not to the general population.

## **MATERIALS AND METHODS**

### **Cells**

The human T-cell line Jurkat clone E6-1 was acquired from ATCC (TIB-152) and was maintained in complete RPMI 1640 supplemented with 5% fetal bovine serum (FBS, Sigma) in a 5% CO<sub>2</sub> incubator. Human embryonic kidney HEK293T cells (ATCC CRL-3216) were maintained in DMEM supplemented with 10% FBS in a 5% CO<sub>2</sub> incubator. All cell lines were routinely tested for the absence of mycoplasma.

### **Lentiviral vector and Jurkat cell transduction**

The generation of Jurkat-S cells expressing the spike protein of the Wuhan variant has been previously described<sup>13</sup>. To express the full-length spike S protein of the Alpha (B.1.1.7), Delta (B.1.617.2) and Kappa (B.1.617.1) SARS-CoV-2 variants in the Jurkat cell line, we used the lentiviral vector based on the epHIV-7 plasmid and the spike S proteins sequences were obtained from the Public Health England database (<https://www.gov.uk/coronavirus>) and synthesized by the company Eurofins Genomics. Wuhan and Alpha (B.1.1.7) variants were expressed in Jurkat CD3<sup>+</sup> cells while Delta (B.1.617.2) and Kappa (B.1.617.1) variants were expressed in Jurkat CD3<sup>-</sup> cells. The Jurkat CD3<sup>-</sup> cells were generated in our lab using CRISPR/Cas9 system. The EGFP sequence was obtained from the vector pEGFP-C1 (Addgene). Plasmid constructions were generated by the Gibson Assembly<sup>®</sup> method.

For transduction, lentiviral-transducing supernatants were produced from transfected packaging HEK-293T cells as described previously<sup>20</sup>. Briefly, lentiviruses were obtained by co-transfecting plasmids pCMV-dR (gag/pol) and pMD2.G (VSV envelope protein), using the JetPEI transfection reagent (Polyplus Transfection). Viral supernatants were obtained after 24 and 48 hours of transfection. Polybrene (8 µg/mL) was added to the viral supernatants prior to transduction of Jurkat cells. A total of 5x10<sup>5</sup> Jurkat cells were plated in a P24 flat-bottom well in 350 µL of RPMI, and 350 µL of viral supernatant were added. Cells were centrifuged for 90

minutes at 2200 rpm and 32°C and left in culture for 24 hours. Transduced GFP+ or HuEGFRt+ cells were selected by FACS sorting 48 h later and expanded in culture.

### **Human sera**

A total of 700 human sera were tested. A first set of 50 sera from Empireo obtained in the year 2020 after the first wave of the COVID-19 pandemics. Serum donors filled in a questionnaire to allow their clinical classification according to the following parameters: Asymptomatic, no symptoms; Mild, 3 or more of the following symptoms: non-productive cough, hyperthermia, headache, odynophagia, dyspnea, asthenia, myalgia, ageusia, anosmia, cutaneous involvement; Moderate, 3 or more of the above symptoms plus gastrointestinal symptoms, or more than 3 of the above for 7 or more days; Moderate-Severe, 3 or more of the above symptoms plus pneumonia; Severe, pneumonia requiring hospitalization and intubation. A second set of 52 serum samples were selected from the study “Immune response dynamics as predictor of COVID-19 disease evolution. Implications for therapeutic decision-making” from the Hospital Universitario La Princesa (HUP) approved by the Research Ethics Committee (no. #4070). A third set of 250 sera from nursery homes and VITRO employees. A fourth set of 40 serum samples were obtained from teachers and employees of a secondary school in Madrid (name not revealed to keep anonymity). Finally, a fifth cohort of 250 serum samples were obtained from capillary blood of volunteers working at the CBMSO in the period of January-July 2021, included in the study “*ACE2 as a biomarker with utility for identification of high risk population for SARS-CoV-2 infection and prognosis of evolution in COVID-19*” approved by the Research Ethics Committee (no. #2352). All participants provided written consent to participate in the study which was performed according to the EU guidelines and following the ethical principles of the Declaration of Helsinki.

### **Flow cytometry**

For the study of relative binding of antibodies to the Alpha versus the Wuhan variants, a 1:1 mix of Jurkat-S(wuhan) and Jurkat-S(Alpha) cells were incubated for 30 min on ice with 1:50 dilutions of human sera in phosphate-buffered saline (PBS), 1% bovine serum albumin (BSA), 0.02% sodium azide. Cells were spun for 5 min at 900 g and the pellet was resuspended in PBS-BSA buffer and spun to eliminate the excess of antibody. Two additional washes were carried out. The cell pellet was finally resuspended in a 1:200 dilution of mouse anti-human IgG1 Fc-PE (Ref.: 9054-09, Southern Biotech) and a 1:200 dilution of the Brilliant Violet 421™ anti-human EGFR Antibody (Ref.: 352911, Biolegend) in PBS-BSA. Samples were then washed, labeled with the viability dye 7AAD and analyzed on a FACSCanto II flow cytometer (Becton-Dickinson) and the data were analyzed with FlowJo software (BD). For the study of the four variants simultaneously, 1:1:1:1 mix of Jurkat-S(wuhan), Jurkat-S(Alpha) Jurkat-S(Delta) and Jurkat-S(Kappa) cells were incubated as previously described, but adding in a dilution 1:200 of the APC anti-human CD3 antibody (BD Ref.: 317317) to discriminate between CD3<sup>+</sup> and CD3<sup>-</sup> cells.

### **Statistics**

One-way ANOVA tests for column analysis of different groups. All data was analyzed using the GraphPad Prism 7 software.

Serum samples were received coded from the providers and the experimentalists were blinded to their nature until all data analysis was finalized. Sample analysis was carried out in duplicate or triplicate and all experiments were repeated a minimum of two times.

### **DATA AVAILABILITY**

This study includes no data deposited in external repositories. Jurkat-S cells are available for academic research upon request to B. Alarcón.

## REFERENCES

1. Polack, F. P. *et al.* Safety and Efficacy of the BNT162b2 mRNA Covid-19 Vaccine. *N. Engl. J. Med.* **383**, 2603–2615 (2020).
2. Voysey, M. *et al.* Safety and efficacy of the ChAdOx1 nCoV-19 vaccine (AZD1222) against SARS-CoV-2: an interim analysis of four randomised controlled trials in Brazil, South Africa, and the UK. *Lancet Lond. Engl.* **397**, 99–111 (2021).
3. Baden, L. R. *et al.* Efficacy and Safety of the mRNA-1273 SARS-CoV-2 Vaccine. *N. Engl. J. Med.* **384**, 403–416 (2021).
4. Sadoff, J. *et al.* Safety and Efficacy of Single-Dose Ad26.COV2.S Vaccine against Covid-19. *N. Engl. J. Med.* **384**, 2187–2201 (2021).
5. Greinacher, A. *et al.* Thrombotic Thrombocytopenia after ChAdOx1 nCov-19 Vaccination. *N. Engl. J. Med.* **384**, 2092–2101 (2021).
6. Muir, K.-L., Kallam, A., Koepsell, S. A. & Gundabolu, K. Thrombotic Thrombocytopenia after Ad26.COV2.S Vaccination. *N. Engl. J. Med.* **384**, 1964–1965 (2021).
7. Planas, D. *et al.* Reduced sensitivity of SARS-CoV-2 variant Delta to antibody neutralization. *Nature* (2021) doi:10.1038/s41586-021-03777-9.
8. Puranik, A. *et al.* Comparison of two highly-effective mRNA vaccines for COVID-19 during periods of Alpha and Delta variant prevalence.  
<http://medrxiv.org/lookup/doi/10.1101/2021.08.06.21261707> (2021)  
doi:10.1101/2021.08.06.21261707.
9. Brown, C. M. *et al.* Outbreak of SARS-CoV-2 Infections, Including COVID-19 Vaccine Breakthrough Infections, Associated with Large Public Gatherings — Barnstable County, Massachusetts, July 2021. *MMWR Morb. Mortal. Wkly. Rep.* **70**, (2021).
10. Werbel, W. A. *et al.* Safety and Immunogenicity of a Third Dose of SARS-CoV-2 Vaccine in Solid Organ Transplant Recipients: A Case Series. *Ann. Intern. Med.* L21-0282 (2021)  
doi:10.7326/L21-0282.

11. Venter, M. & Richter, K. Towards effective diagnostic assays for COVID-19: a review. *J. Clin. Pathol.* **73**, 370–377 (2020).
12. Weissleder, R., Lee, H., Ko, J. & Pittet, M. J. COVID-19 diagnostics in context. *Sci. Transl. Med.* **12**, eabc1931 (2020).
13. Horndler, L. *et al.* Flow cytometry multiplexed method for the detection of neutralizing human antibodies to the native SARS-CoV-2 spike protein. *EMBO Mol. Med.* **13**, e13549 (2021).
14. Burton, D. R. & Hangartner, L. Broadly Neutralizing Antibodies to HIV and Their Role in Vaccine Design. *Annu. Rev. Immunol.* **34**, 635–659 (2016).
15. van Schooten, J. & van Gils, M. J. HIV-1 immunogens and strategies to drive antibody responses towards neutralization breadth. *Retrovirology* **15**, 74 (2018).
16. Kubo, M. & Miyauchi, K. Breadth of Antibody Responses during Influenza Virus Infection and Vaccination. *Trends Immunol.* **41**, 394–405 (2020).
17. Tea, F. *et al.* SARS-CoV-2 neutralizing antibodies: Longevity, breadth, and evasion by emerging viral variants. *PLOS Med.* **18**, e1003656 (2021).
18. Vesper, N. *et al.* A Barcoded Flow Cytometric Assay to Explore the Antibody Responses Against SARS-CoV-2 Spike and Its Variants. *Front. Immunol.* **12**, 730766 (2021).
19. Irani, V. *et al.* Molecular properties of human IgG subclasses and their implications for designing therapeutic monoclonal antibodies against infectious diseases. *Mol. Immunol.* **67**, 171–182 (2015).
20. Martinez-Martin, N. *et al.* Cooperativity between T cell receptor complexes revealed by conformational mutants of CD3epsilon. *Sci Signal* **2**, ra43. (2009).

**Acknowledgments:** We are indebted to Valentina Blanco and Tania Gómez for their expert technical assistance. We thank all volunteers of the CBM, school teachers, “Hospital 12 de Octubre” and “Hospital Universitario de la Princesa” for generously participating in the study.

**Funding:** This work was funded by intramural grant CSIC-COVID19-004: 202020E081 (to B.A.) and CSIC-COVID19-004: 202020E165 (to MF). L.H has been supported by an FPI fellowship from the Spanish Ministry of Science and Innovation. I.B. has been supported by an H2020-MSCA-ITN-2016 training network grant of the European Union (GA 721358). **Author contributions:** LH and PD performed research and analyzed the data; IB helped with experimentation; SR-P, MQ, RL-G, PA-V, MAL, E.-A., SA, and AO provided clinical samples and data and revised the manuscript; MF and HMvS analyzed data and supervised research, BA supervised and designed research, analyzed data and wrote the manuscript.

**Conflict of interest:** The authors have issued a patent application owned by CSIC.

## FIGURE LEGENDS

### **Figure 1. Generation of anti-S protein antibodies in response to the first and second priming-booster doses of different vaccines.**

**(A)** Generation of antibodies against the S protein of the Wuhan strain 3 weeks (BNT) or 4 weeks (Moderna, ChAd and Ad26) after the first, priming, dose of vaccine to previously uninfected individuals. The ratio of the mean fluorescence intensities (MFI) of anti-S staining and anti-EGFR staining was calculated for each serum sample and normalized to the value of the positive control (C+) sample. All sera were used at a 1:50 dilution. Box and whiskers plots to represent minimum and maximum values as well as the median, and the mean (the mean with a cross) is shown. \*  $p < 0.05$ ; \*\*  $p < 0.01$ ; \*\*\*  $p < 0.001$ ; \*\*\*\*  $p < 0.0001$ ; ns, not significant (one-way ANOVA test).

**(B)** Generation of antibodies against the S protein of the Wuhan variant strain 3 weeks (BNT) or 4 weeks (Moderna, ChAd and Ad26) after the first, priming, dose of vaccine and 4 weeks (all vaccines) after the second, booster dose of vaccine. The ratio mean fluorescence intensities (MFI) of anti-S staining and anti-EGFR staining was calculated for each serum sample and normalized to the value of the positive control (C+) sample. All sera were used at a 1:50 dilution. Box and whiskers plots to represent minimum and maximum values as well as the median, and the mean (the mean with a cross) are shown. The number of samples for each vaccine is shown in the graph. \*\*  $p < 0.01$ ; \*\*\*\*  $p < 0.0001$ ; ns, not significant (one-way ANOVA test).

### **Figure 2. Effect of vaccination on the relative recognition of the Alpha and Wuhan variants by sera of vaccinated individuals.**

**(A)** Generation of antibodies against the S protein of the Alpha variant 3 weeks (BNT) or 4 weeks (Moderna, ChAd and Ad26) after the first, priming, dose of vaccine and 4 weeks (all vaccines) after the second, booster dose of vaccine. The ratio mean fluorescence intensities (MFI) of anti-S staining and GFP staining was calculated for each serum sample and normalized to the value

of the positive control (C+) sample. All sera were used at a 1:50 dilution. Box and whiskers plots to represent minimum and maximum values as well as the median, and the mean (the mean with a cross) are shown. The number of samples for each vaccine is shown in the graph. \*\*  $p < 0.01$ ; \*\*\*\*  $p < 0.0001$ ; ns, not significant (one-way ANOVA test).

**(B)** Gating strategy to measure binding to the Wuhan and Alpha variants. Jurkat-S(Wuhan) and Jurkat-S(Alpha) cells were mixed in 1:1 ratio and incubated with either a 1:50 dilution of a positive control serum (C+) from a patient of the first wave in 2020 or a negative control serum (C-) obtained before the COVID-19 pandemics. Cells were subsequently incubated with mouse anti-human IgG1-PE and mouse anti-human EGFR-BV421 antibodies. After incubation, cells were gated according to lymphocyte FSC-A and SSC-A and subsequently on 7-AAD negative cells (7-AAD+ are dead cells). Live cells were subsequently gated on the FL1 channel (for GFP+ cells) and on the FL7 channel (huEGFRt+ cells). Both GFP+ and huEGFRt+ cells were separately analyzed for the fluorescence intensity of anti-IgG1 (S protein, FL2) versus GFP (for Jurkat-S(Alpha)) or for the fluorescence intensity of anti-IgG1 (S protein, FL2) versus EGFR (for Jurkat-S(Wuhan)). A diagonal lane is plotted on the bicolor contour plots corresponding to the C+ staining to indicate a relationship between S protein expression and either GFP or huEGFRt.

**(C)** Relative reactivity of the sera tested in (A) against the Alpha and Wuhan variants measured according to the (S/GFP ratio) / (S/EGFR ratio) and plotted individually for each serum donor. \*\*\*\*  $p < 0.0001$ ; ns, not significant (one-way ANOVA test).

**Figure 3. Multiplexed method to measure the reactivity of IgG1 antibodies with the S protein of the Wuhan, Alpha, Delta and Kappa variants.**

Gating strategy to measure binding to the Wuhan, Alpha, Delta and Kappa variants. Jurkat-S(Wuhan), Jurkat-S(Alpha), Jurkat-S(Delta) and Jurkat-S(Kappa) cells were mixed in 1:1:1:1 ratio and incubated with either a 1:50 dilution of a positive control serum (C+) from a patient of the first wave in 2020 or a negative control serum (C-) obtained before the COVID-19 pandemics.

Cells were subsequently incubated with mouse anti-human IgG1-PE, mouse anti-CD3-APC and mouse anti-human EGFR-BV421 antibodies. After incubation, cells were gated according to lymphocyte FSC-A and SSC-A and subsequently on 7-AAD negative cells (7-AAD<sup>+</sup> are dead cells). Live cells were subsequently gated on the FL1 channel (for CD3<sup>+</sup> cells) and on the FL7 channel (huEGFR<sup>t+</sup> cells). This allowed to distinguish four populations of cells: EGFR<sup>+</sup>CD3<sup>+</sup> (Jurkat-S[Wuhan], EGFR<sup>-</sup>CD3<sup>+</sup> (Jurkat-S[Alpha]), EGFR<sup>+</sup>CD3<sup>-</sup> (Jurkat-S[Delta]) and EGFR<sup>-</sup>CD3<sup>-</sup> (Jurkat-S[Kappa]). The cells were split between CD3<sup>+</sup> and CD3<sup>-</sup> cells and subsequently analyzed according to EGFR and GFP expression (FL7 and FL1 channels). The four cell populations were separately analyzed for the fluorescence intensity of anti-IgG1 (S protein, FL2) versus GFP (for Jurkat-S[Alpha] and Jurkat-S[Kappa]) and for the fluorescence intensity of anti-IgG1 (S protein, FL2) versus EGFR (for Jurkat-S[Wuhan] and Jurkat-S[Delta]). A diagonal lane is plotted on the bicolor contour plots corresponding to the C<sup>+</sup> staining to indicate a relationship between S protein expression and either GFP or huEGFR<sup>t</sup>.

**Figure 4. Follow-up of the antibody response to vaccination in nursing homes.**

**(A)** Generation of antibodies against the S protein of the Wuhan, Alpha, Delta and Kappa variants before (pre-Vacc) and after vaccination with the first dose (PD1) and the second dose (PD2) of BNT/Pfizer. The normalized S/EGFR ratio for reactivity with the Wuhan and Delta variants, and the S/GFP ratio for reactivity with the Alpha and Kappa variants was measured as a quantitative calculation of IgG1 anti-S antibody content. Sera were all used at a 1:50 dilution. Box and whiskers plots to represent minimum and maximum values as well as the median, and the mean (the mean with a cross) are shown. \*  $p < 0.05$ ; \*\*  $p < 0.01$ ; \*\*\*\*  $p < 0.0001$  (one-way ANOVA test).

**(B)** Relative reactivity of the sera tested in (A) against the Alpha, Delta and Kappa variants versus the Wuhan strain was calculated according to the ratio of S/EGFR or S/GFP ratios and plotted individually for each serum donor. \*\*\*\*  $p < 0.0001$  (one-way ANOVA test).


## EXPANDED VIEW FIGURES

### **Figure EV1. Alignment of the amino acid sequences of the S protein of the Wuhan, Alpha, Delta and Kappa variants of SARS-CoV-2.**

Amino acid mutations found in the Alpha, Delta or Kappa variants are shown in red bold type.

Alpha has 5 amino acid replacements and two amino acid deletions compared to the reference Wuhan strain; Delta has 3 amino acid replacements and Kappa has 4. The sequence corresponding to the Receptor Binding Domain (RBD) is boxed. Alpha has just one amino acid (N to Y) replacement in the RBD, Kappa two (L to R and E to Q) and Delta one (L to R).

A



B






Figure 1

A



B



C




Figure 2





Figure 3

A



B




Figure 4

Wuhan	1	MLLLVTSLLLCCLPHPAFLIPQCVNLTRRTQLPPAYTNSFTRGVYYPDKVFRSSVLHSTQDLFLPFFSNVTFWFAIHVSGTNGTKRFDN
Alpha	1	MLLLVTSLLLCCLPHPAFLIPQCVNLTRRTQLPPAYTNSFTRGVYYPDKVFRSSVLHSTQDLFLPFFSNVTFWFAI--SGTNGTKRFDN
Kappa	1	MLLLVTSLLLCCLPHPAFLIPQCVNLTRRTQLPPAYTNSFTRGVYYPDKVFRSSVLHSTQDLFLPFFSNVTFWFAIHVSGTNGTKRFDN
Delta	1	MLLLVTSLLLCCLPHPAFLIPQCVNLTRRTQLPPAYTNSFTRGVYYPDKVFRSSVLHSTQDLFLPFFSNVTFWFAIHVSGTNGTKRFDN
Wuhan	91	PVLPFNDGVYFASTTEKSNIIIRGWIFGTTLDLSDKTSLLIVNNATNVVIVKVECFQFCNDPFLGVYHKNKNSWMESEFRVYSSANNCTFEYV
Alpha	89	PVLPFNDGVYFASTTEKSNIIIRGWIFGTTLDLSDKTSLLIVNNATNVVIVKVECFQFCNDPFLGV-YHKNKNSWMESEFRVYSSANNCTFEYV
Kappa	91	PVLPFNDGVYFASTTEKSNIIIRGWIFGTTLDLSDKTSLLIVNNATNVVIVKVECFQFCNDPFLGVYHKNKNSW <sup>K</sup> SEFRVYSSANNCTFEYV
Delta	91	PVLPFNDGVYFASTTEKSNIIIRGWIFGTTLDLSDKTSLLIVNNATNVVIVKVECFQFCNDPFLGVYHKNKNSW <sup>K</sup> SEFRVYSSANNCTFEYV
Wuhan	181	SQPFLMDLEGKQGNFKNREFVFNKIDGYFKIYSKHTPINLVRDLPQGFSALEPLVDLPIGINITRFQTLALHRSYLPDGDSSSGWTAG
Alpha	178	SQPFLMDLEGKQGNFKNREFVFNKIDGYFKIYSKHTPINLVRDLPQGFSALEPLVDLPIGINITRFQTLALHRSYLPDGDSSSGWTAG
Kappa	181	SQPFLMDLEGKQGNFKNREFVFNKIDGYFKIYSKHTPINLVRDLPQGFSALEPLVDLPIGINITRFQTLALHRSYLPDGDSSSGWTAG
Delta	181	SQPFLMDLEGKQGNFKNREFVFNKIDGYFKIYSKHTPINLVRDLPQGFSALEPLVDLPIGINITRFQTLALHRSYLPDGDSSSGWTAG
Wuhan	271	AAAYVGYLQPRTFLLKYNENGTITDAVDCALDPLSETKCTLSFTVEKGIYQTSNFRVQPTESIVRFPNIITNLCPFGEVFNATRFASVY
Alpha	268	AAAYVGYLQPRTFLLKYNENGTITDAVDCALDPLSETKCTLSFTVEKGIYQTSNFRVQPTESIVRFPNIITNLCPFGEVFNATRFASVY
Kappa	271	AAAYVGYLQPRTFLLKYNENGTITDAVDCALDPLSETKCTLSFTVEKGIYQTSNFRVQPTESIVRFPNIITNLCPFGEVFNATRFASVY
Delta	271	AAAYVGYLQPRTFLLKYNENGTITDAVDCALDPLSETKCTLSFTVEKGIYQTSNFRVQPTESIVRFPNIITNLCPFGEVFNATRFASVY
Wuhan	361	AWNRRKISNCVADYSVLVNSASFSTFKCYGVSPKLNLDLCTNNVYADSFVIRGDEVQRQIAPGQTKGIADYNYKLPDDFTGCVIAWNSNLL
Alpha	358	AWNRRKISNCVADYSVLVNSASFSTFKCYGVSPKLNLDLCTNNVYADSFVIRGDEVQRQIAPGQTKGIADYNYKLPDDFTGCVIAWNSNLL
Kappa	361	AWNRRKISNCVADYSVLVNSASFSTFKCYGVSPKLNLDLCTNNVYADSFVIRGDEVQRQIAPGQTKGIADYNYKLPDDFTGCVIAWNSNLL
Delta	361	AWNRRKISNCVADYSVLVNSASFSTFKCYGVSPKLNLDLCTNNVYADSFVIRGDEVQRQIAPGQTKGIADYNYKLPDDFTGCVIAWNSNLL
Wuhan	451	DSKVGGNYNLYRLFRKSNLKPFRDISEIYQAGSTPCNGVEGFNCFYPLQSYGFQPTNGVGYQPYRVVLSFELLHAPATVCGFKKST
Alpha	448	DSKVGGNYNLYRLFRKSNLKPFRDISEIYQAGSTPCNGVEGFNCFYPLQSYGFQPTNGVGYQPYRVVLSFELLHAPATVCGFKKST
Kappa	451	DSKVGGNYNLYRLFRKSNLKPFRDISEIYQAGSTPCNGV <sup>Q</sup> GFNCFYPLQSYGFQPTNGVGYQPYRVVLSFELLHAPATVCGFKKST
Delta	451	DSKVGGNYNLYRLFRKSNLKPFRDISEIYQAGSTPCNGVEGFNCFYPLQSYGFQPTNGVGYQPYRVVLSFELLHAPATVCGFKKST
Wuhan	541	NLVKKNKCVNFFNGLTGTGVLTESNKKFLPFQFGRDIADTTDAVRDPQTLLEILDITPCSFGGVSVITPGTNTSNQVAVLYQDVNCTEVP
Alpha	538	NLVKKNKCVNFFNGLTGTGVLTESNKKFLPFQFGRDIADTTDAVRDPQTLLEILDITPCSFGGVSVITPGTNTSNQVAVLYQDVNCTEVP
Kappa	541	NLVKKNKCVNFFNGLTGTGVLTESNKKFLPFQFGRDIADTTDAVRDPQTLLEILDITPCSFGGVSVITPGTNTSNQVAVLYQDVNCTEVP
Delta	541	NLVKKNKCVNFFNGLTGTGVLTESNKKFLPFQFGRDIADTTDAVRDPQTLLEILDITPCSFGGVSVITPGTNTSNQVAVLYQDVNCTEVP
Wuhan	631	VAIHADQLTPTWRVYSTGSNVFQTRAGCLIGAHEVNSYECDIPIGAGICASYQTQNSPRRARSVASQSIIAYTMSLGAENSVAYSNNNS
Alpha	628	VAIHADQLTPTWRVYSTGSNVFQTRAGCLIGAHEVNSYECDIPIGAGICASYQTQNS <sup>HRR</sup> ARSVASQSIIAYTMSLGAENSVAYSNNNS
Kappa	631	VAIHADQLTPTWRVYSTGSNVFQTRAGCLIGAHEVNSYECDIPIGAGICASYQTQNS <sup>HRR</sup> ARSVASQSIIAYTMSLGAENSVAYSNNNS
Delta	631	VAIHADQLTPTWRVYSTGSNVFQTRAGCLIGAHEVNSYECDIPIGAGICASYQTQNS <sup>HRR</sup> ARSVASQSIIAYTMSLGAENSVAYSNNNS
Wuhan	721	IAIPTNFTISVTTEILPVSMKTSVDCTMYICGDSTECNSLLQYGSFCTQLNRLTGIAVEQDKNTQEVFAQVKQIYKTPPIKDFGGFN
Alpha	718	IAIP <sup>N</sup> FTISVTTEILPVSMKTSVDCTMYICGDSTECNSLLQYGSFCTQLNRLTGIAVEQDKNTQEVFAQVKQIYKTPPIKDFGGFN
Kappa	721	IAIPTNFTISVTTEILPVSMKTSVDCTMYICGDSTECNSLLQYGSFCTQLNRLTGIAVEQDKNTQEVFAQVKQIYKTPPIKDFGGFN
Delta	721	IAIPTNFTISVTTEILPVSMKTSVDCTMYICGDSTECNSLLQYGSFCTQLNRLTGIAVEQDKNTQEVFAQVKQIYKTPPIKDFGGFN
Wuhan	811	FSQILPDPSPKRSFIEDLLFNKVTLADAGFIKQYGDCLGDI AARDL ICAQKFNGLTVLPLLLTDEMIAQYTSALLAGTITSGWTFGAG
Alpha	808	FSQILPDPSPKRSFIEDLLFNKVTLADAGFIKQYGDCLGDI AARDL ICAQKFNGLTVLPLLLTDEMIAQYTSALLAGTITSGWTFGAG
Kappa	811	FSQILPDPSPKRSFIEDLLFNKVTLADAGFIKQYGDCLGDI AARDL ICAQKFNGLTVLPLLLTDEMIAQYTSALLAGTITSGWTFGAG
Delta	811	FSQILPDPSPKRSFIEDLLFNKVTLADAGFIKQYGDCLGDI AARDL ICAQKFNGLTVLPLLLTDEMIAQYTSALLAGTITSGWTFGAG
Wuhan	901	AALQIPFAMQMAYRFNGIGVTQNVLYENQKLIANQFNSAIGKIQDLSSTASALGKLDVVNQNAQALNTLVKQLSSNFGAISVNDIL
Alpha	898	AALQIPFAMQMAYRFNGIGVTQNVLYENQKLIANQFNSAIGKIQDLSSTASALGKLDVVNQNAQALNTLVKQLSSNFGAISVNDIL
Kappa	901	AALQIPFAMQMAYRFNGIGVTQNVLYENQKLIANQFNSAIGKIQDLSSTASALGKLDVVNQNAQALNTLVKQLSSNFGAISVNDIL
Delta	901	AALQIPFAMQMAYRFNGIGVTQNVLYENQKLIANQFNSAIGKIQDLSSTASALGKLDVVNQNAQALNTLVKQLSSNFGAISVNDIL
Wuhan	991	SRLDKVEAEVQIDRLITGRLQSLQTYVTQQLIRAAEIRASANLAATKMSECVLGGQSKRVDFCGKGYHLMSPQSA <sup>H</sup> PHGVVFLHVTYVPAQ
Alpha	988	SRLDKVEAEVQIDRLITGRLQSLQTYVTQQLIRAAEIRASANLAATKMSECVLGGQSKRVDFCGKGYHLMSPQSA <sup>H</sup> PHGVVFLHVTYVPAQ
Kappa	991	SRLDKVEAEVQIDRLITGRLQSLQTYVTQQLIRAAEIRASANLAATKMSECVLGGQSKRVDFCGKGYHLMSPQSA <sup>H</sup> PHGVVFLHVTYVPAQ
Delta	991	SRLDKVEAEVQIDRLITGRLQSLQTYVTQQLIRAAEIRASANLAATKMSECVLGGQSKRVDFCGKGYHLMSPQSA <sup>H</sup> PHGVVFLHVTYVPAQ
Wuhan	1081	EKNFTTAPAI <sup>H</sup> CHDGKAHFPREGVFSNGTHWFVTQRNFYEPQIITTDNTFVSGNCDVVIGIVNNTVYDPLQPELDSFKEELDKYFKNHTS
Alpha	1078	EKNFTTAPAI <sup>H</sup> CHDGKAHFPREGVFSNGTHWFVTQRNFYEPQIIT <sup>H</sup> NTFVSGNCDVVIGIVNNTVYDPLQPELDSFKEELDKYFKNHTS
Kappa	1081	EKNFTTAPAI <sup>H</sup> CHDGKAHFPREGVFSNGTHWFVTQRNFYEPQIITTDNTFVSGNCDVVIGIVNNTVYDPLQPELDSFKEELDKYFKNHTS
Delta	1081	EKNFTTAPAI <sup>H</sup> CHDGKAHFPREGVFSNGTHWFVTQRNFYEPQIITTDNTFVSGNCDVVIGIVNNTVYDPLQPELDSFKEELDKYFKNHTS
Wuhan	1171	PDVDLGDISGINASVVNIQKEIDRLNEVAKNLNESLIDLQELGKYEQYIKWPWYIWLGFIAGLIAIVMVTIMLCCMTSCCSCLKGCCSCG
Alpha	1168	PDVDLGDISGINASVVNIQKEIDRLNEVAKNLNESLIDLQELGKYEQYIKWPWYIWLGFIAGLIAIVMVTIMLCCMTSCCSCLKGCCSCG
Kappa	1171	PDVDLGDISGINASVVNIQKEIDRLNEVAKNLNESLIDLQELGKYEQYIKWPWYIWLGFIAGLIAIVMVTIMLCCMTSCCSCLKGCCSCG
Delta	1171	PDVDLGDISGINASVVNIQKEIDRLNEVAKNLNESLIDLQELGKYEQYIKWPWYIWLGFIAGLIAIVMVTIMLCCMTSCCSCLKGCCSCG
Wuhan	1261	SCCKFDEDDSEPV <sup>L</sup> LKGVK <sup>L</sup> LHYT
Alpha	1258	SCCKFDEDDSEPV <sup>L</sup> LKGVK <sup>L</sup> LHYT
Kappa	1261	SCCKFDEDDSEPV <sup>L</sup> LKGVK <sup>L</sup> LHYT
Delta	1261	SCCKFDEDDSEPV <sup>L</sup> LKGVK <sup>L</sup> LHYT

RBD